<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639883</url>
  </required_header>
  <id_info>
    <org_study_id>AIV001-W01</org_study_id>
    <nct_id>NCT03639883</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study to Evaluate Wound Healing</brief_title>
  <official_title>A Randomized, Double-blind, Vehicle-controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intradermally Administered AIV001 in the Healing of Incisional Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AiViva BioPharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AiViva BioPharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, efficacy and pharmacokinetic profile of ascending concentrations of
      the study medication compared with vehicle in subjects with incisional wounds
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is primarily a safety study to evaluate the safety of AIV001 when administered near
      incisional wounds. Exploratory efficacy measures will also be collected as well as
      pharmacokinetic profiles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2018</start_date>
  <completion_date type="Actual">December 19, 2019</completion_date>
  <primary_completion_date type="Actual">December 4, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, vehicle-controlled, dose-escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Treating investigator will administer the study medication. Evaluating Investigator will perform the safety and efficacy evaluations.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 1 through Day 49</time_frame>
    <description>Local and systemic adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy using Patient and Observer Scar Assessment Scale (6 parameters, 1 normal to 10 worst imaginable)</measure>
    <time_frame>Day 7 through 49</time_frame>
    <description>Evaluation of the healing of the wounds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Vancouver Scar Scale (4 parameters, 0 = normal to 3 or 4 = severe)</measure>
    <time_frame>Day 7 through 49</time_frame>
    <description>Evaluation of the healing wounds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100 mm Visual Analogue Scale (0 = normal to 10 = poor scar)</measure>
    <time_frame>Day 7 through 49</time_frame>
    <description>Evaluation of healing wounds</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Wound Heal</condition>
  <arm_group>
    <arm_group_label>0.033% versus Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One side of the subject will receive 0.033% AIV001 and the other side of the subject will receive vehicle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1% versus Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One side of the subject will receive 0.1% AIV001 and the other side of the subject will receive vehicle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3% versus Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One side of the subject will receive 0.3% AIV001 and the other side of the subject will receive vehicle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1% versus Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One side of the subject will receive 1% AIV001 and the other side of the subject will receive vehicle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AIV001</intervention_name>
    <description>Intradermal injection</description>
    <arm_group_label>0.033% versus Vehicle</arm_group_label>
    <arm_group_label>0.1% versus Vehicle</arm_group_label>
    <arm_group_label>0.3% versus Vehicle</arm_group_label>
    <arm_group_label>1% versus Vehicle</arm_group_label>
    <other_name>AIV001 suspension</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible for an abdominoplasty

          -  Nonsmoker

          -  Fitzpatrick I-IV

          -  Weight &gt;45Kg

          -  BMI &lt;= 35

        Exclusion Criteria:

          -  Existing scars in study area, active infection

          -  Any medical history or present conditions that may increase the risk associated with
             study participation or investigational product administration and, in the judgment of
             the Investigator, would make the subject inappropriate for entry into this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Milbauer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Novella Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cosmetic Laser Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wound healing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

